NR 565 – Advanced Pharmacology Fundamentals
Final Exam Prep Question Bank
Latest 2026/2027
100 Original Practice Questions & Detailed Rationales
Prepared for independent exam preparation and study purposes.
Covers pharmacokinetics, pharmacodynamics, drug classes, safe prescribing,
drug interactions, monitoring, and advanced clinical decision-making.
,How to Use This Question Bank
This exam prep guide contains 100 original, comprehensive multiple-choice questions designed to reflect
the breadth and depth of a graduate-level Family Nurse Practitioner pharmacology final examination.
Questions integrate pharmacokinetic and pharmacodynamic principles, medication safety, drug
interactions, contraindications, monitoring parameters, and realistic clinical scenarios.
For best results, attempt each question independently before reviewing the correct answer and
rationale. Rationales explain not only why the correct answer is appropriate, but also why the remaining
options are less suitable, reinforcing clinical reasoning rather than simple memorization.
Topics are intentionally interwoven throughout the exam, rather than grouped by category, to simulate
the unpredictable nature of a comprehensive final examination and to strengthen your ability to shift
between pharmacologic concepts quickly and accurately.
,Question 1. A patient with an active peptic ulcer requires cardioprotective antiplatelet therapy following
myocardial infarction. Which approach best balances these competing risks?
A. Discontinue antiplatelet therapy entirely to protect the ulcer
B. Continue antiplatelet therapy with concurrent proton pump inhibitor for gastrointestinal
protection
C. Switch to high-dose NSAIDs instead
D. No modification to therapy is needed
Correct Answer: B
Rationale: Continuing necessary antiplatelet therapy after myocardial infarction while adding proton
pump inhibitor therapy reduces gastrointestinal bleeding risk while preserving essential cardioprotection.
Discontinuing antiplatelet therapy risks stent thrombosis or recurrent cardiac events, NSAIDs would
worsen ulcer risk and are not a substitute, and no modification ignores the significant bleeding risk.
Question 2. Which mechanism explains the primary bronchodilator effect of albuterol?
A. Beta-2 adrenergic receptor agonism causing smooth muscle relaxation
B. Muscarinic receptor antagonism
C. Leukotriene receptor blockade
D. Mast cell stabilization
Correct Answer: A
Rationale: Albuterol selectively stimulates beta-2 adrenergic receptors on bronchial smooth muscle,
activating a cascade that leads to smooth muscle relaxation and bronchodilation within minutes.
Muscarinic antagonism describes anticholinergic bronchodilators like ipratropium, leukotriene blockade
describes montelukast's mechanism, and mast cell stabilization describes cromolyn's mechanism, none of
which are albuterol's primary action.
Question 3. Which finding in an elderly patient taking multiple anticholinergic medications would be
most concerning for cumulative anticholinergic burden?
A. Improved short-term memory and alertness
B. New onset confusion, dry mouth, urinary retention, and constipation
C. Decreased heart rate
D. Improved bowel motility
Correct Answer: B
Rationale: Cumulative anticholinergic burden from multiple medications with anticholinergic properties
can manifest as confusion, dry mouth, urinary retention, and constipation, particularly concerning in
elderly patients who are more susceptible to central nervous system effects including delirium. Improved
memory, decreased heart rate, and improved bowel motility are inconsistent with anticholinergic toxicity,
which typically causes tachycardia and reduced motility rather than the opposite effects.
Question 4. A patient with stable angina is prescribed a beta-blocker. Which patient history finding
would be a contraindication to this therapy?
A. Type 2 diabetes mellitus
B. Severe reactive airway disease with frequent bronchospasm
C. Osteoarthritis
, D. Well-controlled hypothyroidism
Correct Answer: B
Rationale: Non-selective beta-blockers can precipitate severe bronchospasm in patients with significant
reactive airway disease, making this a relative to absolute contraindication depending on severity.
Diabetes requires caution regarding masked hypoglycemia symptoms but is not an absolute
contraindication, while osteoarthritis and controlled hypothyroidism are not relevant contraindications.
Question 5. A patient with a history of Stevens-Johnson syndrome from a sulfonamide antibiotic requires
treatment for a urinary tract infection. What is the most appropriate action?
A. Prescribe the same sulfonamide antibiotic at a lower dose
B. Avoid all sulfonamide-containing medications and select an alternative antibiotic class
C. Prescribe a different sulfonamide antibiotic, since cross-reactivity is not a concern
D. Administer a test dose under observation
Correct Answer: B
Rationale: A history of Stevens-Johnson syndrome, a severe and potentially life-threatening
hypersensitivity reaction, is an absolute contraindication to re-exposure to the causative drug class,
requiring selection of an entirely different antibiotic class for future infections. Rechallenging at a lower
dose, using a different sulfonamide, or attempting a test dose all carry unacceptable risk of triggering
another severe, potentially fatal reaction.
Question 6. Which factor most significantly affects the volume of distribution of a highly lipophilic
medication in an obese patient compared to a lean patient?
A. Volume of distribution decreases due to increased fat storage
B. Volume of distribution increases due to increased fat tissue available for drug storage
C. Volume of distribution is unaffected by body composition
D. Volume of distribution only depends on renal function
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue, so patients with higher body fat
percentage have an increased volume of distribution for these medications, which can affect loading
dose calculations and drug half-life. Body composition significantly influences distribution for lipophilic
drugs, and renal function is not the primary determinant of volume of distribution.
Question 7. Which pharmacokinetic parameter best describes the percentage of an administered drug
dose that reaches systemic circulation unchanged?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Half-life
Correct Answer: B
Rationale: Bioavailability specifically quantifies the fraction of an administered dose reaching systemic
circulation intact, critical when converting between routes of administration. Volume of distribution
describes drug distribution extent, clearance describes elimination rate, and half-life describes time for
concentration to decrease by half.
Final Exam Prep Question Bank
Latest 2026/2027
100 Original Practice Questions & Detailed Rationales
Prepared for independent exam preparation and study purposes.
Covers pharmacokinetics, pharmacodynamics, drug classes, safe prescribing,
drug interactions, monitoring, and advanced clinical decision-making.
,How to Use This Question Bank
This exam prep guide contains 100 original, comprehensive multiple-choice questions designed to reflect
the breadth and depth of a graduate-level Family Nurse Practitioner pharmacology final examination.
Questions integrate pharmacokinetic and pharmacodynamic principles, medication safety, drug
interactions, contraindications, monitoring parameters, and realistic clinical scenarios.
For best results, attempt each question independently before reviewing the correct answer and
rationale. Rationales explain not only why the correct answer is appropriate, but also why the remaining
options are less suitable, reinforcing clinical reasoning rather than simple memorization.
Topics are intentionally interwoven throughout the exam, rather than grouped by category, to simulate
the unpredictable nature of a comprehensive final examination and to strengthen your ability to shift
between pharmacologic concepts quickly and accurately.
,Question 1. A patient with an active peptic ulcer requires cardioprotective antiplatelet therapy following
myocardial infarction. Which approach best balances these competing risks?
A. Discontinue antiplatelet therapy entirely to protect the ulcer
B. Continue antiplatelet therapy with concurrent proton pump inhibitor for gastrointestinal
protection
C. Switch to high-dose NSAIDs instead
D. No modification to therapy is needed
Correct Answer: B
Rationale: Continuing necessary antiplatelet therapy after myocardial infarction while adding proton
pump inhibitor therapy reduces gastrointestinal bleeding risk while preserving essential cardioprotection.
Discontinuing antiplatelet therapy risks stent thrombosis or recurrent cardiac events, NSAIDs would
worsen ulcer risk and are not a substitute, and no modification ignores the significant bleeding risk.
Question 2. Which mechanism explains the primary bronchodilator effect of albuterol?
A. Beta-2 adrenergic receptor agonism causing smooth muscle relaxation
B. Muscarinic receptor antagonism
C. Leukotriene receptor blockade
D. Mast cell stabilization
Correct Answer: A
Rationale: Albuterol selectively stimulates beta-2 adrenergic receptors on bronchial smooth muscle,
activating a cascade that leads to smooth muscle relaxation and bronchodilation within minutes.
Muscarinic antagonism describes anticholinergic bronchodilators like ipratropium, leukotriene blockade
describes montelukast's mechanism, and mast cell stabilization describes cromolyn's mechanism, none of
which are albuterol's primary action.
Question 3. Which finding in an elderly patient taking multiple anticholinergic medications would be
most concerning for cumulative anticholinergic burden?
A. Improved short-term memory and alertness
B. New onset confusion, dry mouth, urinary retention, and constipation
C. Decreased heart rate
D. Improved bowel motility
Correct Answer: B
Rationale: Cumulative anticholinergic burden from multiple medications with anticholinergic properties
can manifest as confusion, dry mouth, urinary retention, and constipation, particularly concerning in
elderly patients who are more susceptible to central nervous system effects including delirium. Improved
memory, decreased heart rate, and improved bowel motility are inconsistent with anticholinergic toxicity,
which typically causes tachycardia and reduced motility rather than the opposite effects.
Question 4. A patient with stable angina is prescribed a beta-blocker. Which patient history finding
would be a contraindication to this therapy?
A. Type 2 diabetes mellitus
B. Severe reactive airway disease with frequent bronchospasm
C. Osteoarthritis
, D. Well-controlled hypothyroidism
Correct Answer: B
Rationale: Non-selective beta-blockers can precipitate severe bronchospasm in patients with significant
reactive airway disease, making this a relative to absolute contraindication depending on severity.
Diabetes requires caution regarding masked hypoglycemia symptoms but is not an absolute
contraindication, while osteoarthritis and controlled hypothyroidism are not relevant contraindications.
Question 5. A patient with a history of Stevens-Johnson syndrome from a sulfonamide antibiotic requires
treatment for a urinary tract infection. What is the most appropriate action?
A. Prescribe the same sulfonamide antibiotic at a lower dose
B. Avoid all sulfonamide-containing medications and select an alternative antibiotic class
C. Prescribe a different sulfonamide antibiotic, since cross-reactivity is not a concern
D. Administer a test dose under observation
Correct Answer: B
Rationale: A history of Stevens-Johnson syndrome, a severe and potentially life-threatening
hypersensitivity reaction, is an absolute contraindication to re-exposure to the causative drug class,
requiring selection of an entirely different antibiotic class for future infections. Rechallenging at a lower
dose, using a different sulfonamide, or attempting a test dose all carry unacceptable risk of triggering
another severe, potentially fatal reaction.
Question 6. Which factor most significantly affects the volume of distribution of a highly lipophilic
medication in an obese patient compared to a lean patient?
A. Volume of distribution decreases due to increased fat storage
B. Volume of distribution increases due to increased fat tissue available for drug storage
C. Volume of distribution is unaffected by body composition
D. Volume of distribution only depends on renal function
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue, so patients with higher body fat
percentage have an increased volume of distribution for these medications, which can affect loading
dose calculations and drug half-life. Body composition significantly influences distribution for lipophilic
drugs, and renal function is not the primary determinant of volume of distribution.
Question 7. Which pharmacokinetic parameter best describes the percentage of an administered drug
dose that reaches systemic circulation unchanged?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Half-life
Correct Answer: B
Rationale: Bioavailability specifically quantifies the fraction of an administered dose reaching systemic
circulation intact, critical when converting between routes of administration. Volume of distribution
describes drug distribution extent, clearance describes elimination rate, and half-life describes time for
concentration to decrease by half.
